Humira® Approved by FDA to Treat Skin Disease
Hidradenitis Suppurativa is a chronic skin condition where tender pimple-like bumps appear in the skin. Most commonly, the bumps develop in the underarms and groin, and the onset of the disease is usually during puberty. Hidradenitis suppurativa can be debilitating for patients because of intense pain, spontaneous rupturing of pus filled bumps, and continued uncontrolled production of new bumps in the affected skin.
The FDA recently approved Humira® (Adalimumab) as the first and only FDA-approved therapy for hidradenitis suppurativa. In the clinical trials, patients who received Humira® had a significant reduction in the number of painful cysts and pus filled bumps compared to those who received placebo. The FDA approval of Humira® for hidradenitis suppurativa will increase patient access to the drug and provide a much needed new development in treatment options for these patients.